Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.67 USD
Change Today -0.009 / -1.33%
Volume 83.0K
BSPM On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biostar pharmaceuticals inc (BSPM) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $2.16
52 Week Low
08/24/15 - $0.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biostar pharmaceuticals inc (BSPM) Related Businessweek News

No Related Businessweek News Found

biostar pharmaceuticals inc (BSPM) Details

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. Its product line also includes 12 other OTC products and 17 prescription-based pharmaceuticals. The company’s OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat pain, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for the treatment of pain and other symptoms associated with menstruation; Deafness Tongqiao pills for the treatment of hepatobiliary Huosheng, head dazzling swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for the treatment of joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Compound Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates, a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People’s Republic of China.

408 Employees
Last Reported Date: 04/15/15
Founded in 2007

biostar pharmaceuticals inc (BSPM) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $17.6K
Interim Chief Financial Officer and Director
Total Annual Compensation: $11.3K
Chief Operating Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

biostar pharmaceuticals inc (BSPM) Key Developments

Biostar Pharmaceuticals Receives Non-Compliance Notification Letter From Nasdaq

On August 24, 2015, Biostar Pharmaceuticals, Inc. received a notification letter (the “Notice”) from Nasdaq Listing Qualifications (“Nasdaq”) advising the Company that based upon the closing bid price for the Company’s common stock for the past 30 consecutive business days, the Company no longer complied with the minimum $1.00 per share Nasdaq continued listing requirement set forth in Nasdaq Listing Rule 5555(a)(2) (the “Minimum Bid Price Rule”). The Notice also stated that the Company would be provided 180 calendar days, or until February 22, 2016 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of 10 consecutive business days prior to that date. If the Company does not regain compliance by the Compliance Deadline, the Company may be eligible for additional time to regain compliance. To qualify for such additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If and to the extent the Company meets these requirements, the Nasdaq staff may grant an additional 180 calendar days. If, however, the Company is unable to cure the deficiency, or if the Company is otherwise not eligible, the Company’s securities will be subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company cannot provide any assurance that its common stock will trade at levels necessary to regain and maintain compliance with the Minimum Bid Price Rule before the Compliance Deadline. The Company intends to continue to monitor the bid price for its common stock. If the Company’s common stock does not trade at a level that is likely to regain compliance with the Nasdaq requirements, the Company’s Board of Directors will consider other options that may be available to achieve compliance.

Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results of the Second Quarter and Six Months Ended June 30, 2015

Biostar Pharmaceuticals, Inc. announced unaudited consolidated earnings results of the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales, net of $14,176,234 against $19,198,854 a year ago. Loss from operations was $1,073,184 against $1,963,182 a year ago. Loss before income taxes was $661,499 against income before income taxes of $1,178,845 a year ago. Net loss was $492,427 or $0.03 per basic and diluted share against net income of $1,645,494 or $0.11 per basic and diluted share a year ago. For the six months, the company's sales, net were $21,084,981 against $32,380,018 a year ago. Loss from operations was $1,963,182 against $307,764 a year ago. Loss before income taxes was $1,300,474 against income before income tax of $1,784,756 a year ago. Net loss was $652,531 or $0.04 per basic and diluted share against net income of $1,952,164 or $0.14 per basic and diluted share a year ago. Net cash provided by operating activities was $439,558 against $1,036,577 a year ago. Purchase of property and equipment was $30,760 against $479,792 a year ago.

Biostar Pharmaceuticals, Inc. announced delayed 10-Q filing

On 08/17/2015, Biostar Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSPM:US $0.67 USD -0.009

BSPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSPM.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSPM Industry Range
Price/Earnings 4.6x
Price/Sales 0.2x
Price/Book 0.1x
Price/Cash Flow 4.6x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSTAR PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at